Kalaris Therapeutics, Inc. (KLRS) stock
KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)
Close on Nov 17, 2026Market cap $34.04MP/E –Yield –
Kalaris Therapeutics EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Kalaris Therapeutics
Kalaris Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?